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Abstract
Background: Although several mathematical models have been proposed to assess the risk:benefit of drugs in one
measure, their use in practice has been rather limited. Our objective was to design a simple, easily applicable model. In this
respect, measuring the proportion of patients who respond favorably to treatment without being affected by adverse drug
reactions (ADR) could be a suitable endpoint. However, remarkably few published clinical trials report the data required to
calculate this proportion. As an approach to the problem, we calculated the expected proportion of this type of patients.
Methodology/Principal Findings: Theoretically, responders without ADR may be obtained by multiplying the total number
of responders by the total number of subjects that did not suffer ADR, and dividing the product by the total number of
subjects studied. When two drugs are studied, the same calculation may be repeated for the second drug. Then, by
constructing a 262 table with the expected frequencies of responders with and without ADR, and non-responders with and
without ADR, the odds ratio and relative risk with their confidence intervals may be easily calculated and graphically
represented on a logarithmic scale. Such measures represent ‘‘net efficacy adjusted for risk’’ (NEAR). We assayed the model
with results extracted from several published clinical trials or meta-analyses. On comparing our results with those originally
reported by the authors, marked differences were found in some cases, with ADR arising as a relevant factor to balance the
clinical benefit obtained. The particular features of the adverse reaction that must be weighed against benefit is discussed in
the paper.
Conclusion: NEAR representing overall risk-benefit may contribute to improving knowledge of drug clinical usefulness. As
most published clinical trials tend to overestimate benefits and underestimate toxicity, our measure represents an effort to
change this trend.
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Introduction
Although several mathematical models have been proposed to
assess risk:benefit balance of drugs in one measure [1–4], their use
in practice has been rather limited. Difficulties in computation as
well as in interpreting results may have hampered a broader use of
these formulations. Our objective was to design a simple, easily
applicable model to overcome such obstacles. To this end, the
following criteria were considered important: a) data for
computation must be easily available; b) risk and benefit must be
combined in a single measure, and c) this measure must be
sufficiently clear to be used in clinical practice.
As to these criteria, data for computation may be extracted from
well known sources, mainly from controlled randomized clinical
trials (CRT) and their meta-analytical reviews; secondarily, results
of observational prospective studies may also be used.
In order to combine efficacy and safety in one easily understand-
able measure, results obtained from CRT may be divided into two
categories: a) patients responding to treatment without suffering
adverse drug reactions (ADR); and b) the remaining patients, i.e. the
sum of those responding to the drug but suffering ADR, plus those
resistant to the treatment but not suffering ADR, plus those resistant
to the treatment and simultaneously suffering ADR. It is clear that
the proportion of patients who respond favorably to treatment
without being affected by ADR is an easily understandable
parameter representing the optimum effect of the drug. However,
in practice, most published data sources fail to report this detail. In
addition, slight ADR do not have the same weight as severe ADR.
Consequently, both problems require discussion and a solution.
Leaving aside for a posterior analysis those aspects related to the
severity of ADR, the number of patients responding to treatment
without suffering ADR is unavailable in most published data
sources, as mentioned above. Indeed, efficacy and safety data are
normally reported separately, as if they had been obtained from
different populations; moreover, the units of measurement
frequently correspond to non-comparable scales of benefit and
risk. Our approach to this problem was to use a statistical
maneuver i.e. expected frequency calculation, which is a well
known step in chi square calculation. In this manner, we were able
to determine the theoretical proportion of patients favorably
responding to the drug without suffering ADR. This measure may
be useful, mainly when two drugs are compared.
As to the question of what type of ADR must be weighed
against the benefit endpoint, the simplest answer is you can do
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answer in practical terms, as will be shown below. In fact there are
no standardized and universal rating scales for categorizing the
severity of ADR. Therefore, selecting an ADR to calculate
risk:benefit balance is better done by taking into consideration
each particular clinical problem. For instance, in selecting between
two opioid analgesics for palliative care, perhaps the ADR that
physicians most like to avoid is vomiting, which, although not a
severe ADR, may hinder the therapeutic efficacy and decrease
patient quality of life. Although detailed severity analysis may be
interesting from an academic or a regulatory point of view, clinical
condition is decisive at the time of selecting what type of drug
therapy must be employed.
Once the above mentioned problems are solved, details about
computation and its application to several practical cases are
shown below.
Methods
As already indicated, theoretically, results obtained in either
CRT or observational studies can be separated into the categories
shown in Table 1.
Whenever these data are originally reported, it is feasible to
calculate the odds ratio (OR) or relative risk (RR); in these cases
safety and efficacy are directly combined. But published studies
practically never present these data, and, consequently, such tables
can not be constructed.
As explained before, a statistical manner of addressing the
problem consists in replacing the observed frequencies by their
expected ones. The procedure is feasible whenever the total number
of patients who responded to treatment favorably as well as the total
number of patients who experienced ADR are reported; happily,
authors do usually report these data. So, the expected frequency for
cell ‘‘a’’ in Table 1 is obtained by multiplying the total number of
responders by the total number of subjects that did not suffer ADR,
and dividing the product by the total number of subjects studied.
Similar calculations may be performed to obtain the expected
frequencies for the remaining cells.
When two drugs are involved, which is the most frequent case in
practice, all the above calculations may be repeated for the second
drug. Once the expected frequencies for the two treatments are
obtained the data may be then organized in the manner indicated
in Table 2.
Thus, the optimum effect corresponds to the cells in the first
column, i.e., a1 and a2. Now, to transform these terms into
epidemiological parameters with their statistical significances,
these data may be reorganized as described in table 3.
Focusing on the data contained in Table 3, let b1+c1+d1=S 1
and b2+c2+d2=S 2. Then a1*S2/a2*S1 expresses the odds ratio for
‘‘net efficacy adjusted for risk’’ (OR NEAR); and (a1/n1)/(a2/n2)
expresses the relative risk for ‘‘net efficacy adjusted for risk’’ (RR
NEAR). Finally, the 95% confidence intervals (CIs) for these new
parameters may be calculated in the following manner [5]:
NEAR OR+CI95 %~NEAR OR  
e+1:96H 1=a1 ðÞ z 1=a2 ðÞ z 1=s1 ðÞ z 1=s2 ðÞ
NEAR RR+CI95 %~NEAR RR  
e+1:96H 1=a1 ðÞ { 1=n1 ðÞ z 1=a2 ðÞ { 1=n2 ðÞ
These NEAR OR and NEAR RR measures represent how
much more beneficial and safe a proband drug is than the control
drug and with what statistical significance. Moreover, these
variables and their confidence intervals may be represented on a
logarithmic scale, so that the statistical significance of differences
between treatments may be visually determined. Naturally, the
higher the sample size, the higher the accuracy of the measure.
To facilitate NEAR calculation, an Excel worksheet has been
developed by the authors. Thus, numerical results as well as
graphic display of NEAR OR and NEAR RR with their 95% CIs
are easily obtained by running the application offered at the
following website: http://investigacion-huc.com.
A preliminary example of calculation and interpretation
of results
To explain how to proceed in practice let us introduce a
preliminary example. Efficacy and safety of two quinolones,
gemifloxacin and trovafloxacin, were compared in a CRT for the
treatment of community-acquired pneumonia [6]. Eligible patients
were randomized to receive either oral gemifloxacin 320 mg once
daily or oral trovafloxacin 200 mg once daily for seven days. The
therapeutic response was defined as the combined clinical (no
further antibiotic therapy was required) and bacteriological
(original pathogens were erradicated) responses. Safety was
Table 1. 262 table combining efficacy and safety results of a
theoretical CRT.
Responders Non-responders
Without ADR a b Total without ADR
Suffering ADR c d Total suffering ADR
Total responders Total non-responders Total studied
doi:10.1371/journal.pone.0003580.t001
Table 2. Table combining efficacy and safety results of a theoretical CRT when two drugs have been studied.
Responders without ADR Responders with ADR Non-responders without ADR Non-responders with ADR Totals
Treatment A a1 c1 b1 d1 n1
Treatment B a2 c2 b2 d2 n2
doi:10.1371/journal.pone.0003580.t002
Table 3. Re-arrangement of results from Table 2 for
calculating OR or RR.
Responders without ADR Other results Total
Drug A a1 b1+c1+d1 n1
Drug B a2 b2+c2+d2 n2
doi:10.1371/journal.pone.0003580.t003
Net Efficacy Adjusted for Risk
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relationship to the study medication; treatment-associated adverse
events leading to withdrawal were also recorded. As to explaining
the procedure, we extracted results (by intention to treat analysis)
corresponding to clinical response for benefit assessment and
adverse events leading to withdrawal for safety assessment. Thus,
290 patients received gemifloxacin treatment; 254 of them (87.6%)
exhibited a favourable clinical response at follow-up; 281 were
treated with trovafloxacin, 228 of them (81.1%) responding
favourably; 5.5% of patients (n=16) in the gemifloxacin group
and 4.6% (n=13) in the trovafloxacin group had to be withdrawn
due to treatment associated adverse events. The authors concluded
that ‘‘gemifloxacin is an effective and well-tolerated treatment for
patients with community-acquired pneumonia’’.
Using the data obtained with gemifloxacin, we constructed
Table 4 where the expected frequencies for each cell were easily
calculated. After repeating calculations for trovafloxacin, Table 5
was constructed.
Now the odds ratio (NEAR OR) and the relative risk (NEAR
RR) with their 95% confidence intervals may be easily computed.
Table 6 shows the results obtained for these parameteres together
with traditional odds ratio and relative risk for efficacy (i.e. without
combining safety data) and for safety (i.e. without combining
efficacy data). Classical NNT (number needed to treat) and NNH
(number needed to harm) are also presented. In this manner the
contribution of NEAR OR or RR to clinical trials or observational
studies assesment may be compared with those of traditional
measures. When the lower limit of the 95% confidence interval is
above 1, the proband drug is deemed better than the control; in
this case, gemifloxacin is the proband drug.
On examining the data contained in the table, if only efficacy
parameters are considered, gemifloxacin seems to be better than
trovafloxacin; if only safety parameters are taken into account, no
differences are found between treatments. Adjusting efficacy for
safety in one measure, i.e NEAR OR and RR, it can be seen that
no significant differences between the two treatments were
observed. Therefore, the authors’ narrative conclusion indicating
that ‘‘gemifloxacin is an effective and well-tolerated treatment’’
may be better expressed by saying that according to the data
reported gemifloxacin was as effective and safe as trovafloxacin.
Assaying the model
To assay our model, a further series of examples selected from
the literature was tested. Selection was made by applying the
following criteria: firstly, cases arising from clinical practice, in
which patient features required a particular management; in a
more general setting, a second criterion was drugs recently
introduced on the market, about which physicians usually like to
know their actual advantages; and thirdly, cases in which
prevention rather than a clinical change was the endpoint, safety
being a critical aspect in these cases.
Finally, expected frequencies were compared with real frequen-
cies. In this respect one rare study reporting the data required was
used [1].
Results
In Figure 1, graphics for OR may be seen. This figure is an
example of the possibilities of graphic representation of data.
Numerical data for RR as well as for NNT and NNH are
summarized in Tables 7, 8 and 9.
Cases arising from clinical practice
The first example corresponded to a comparison of ibuprofen
and indomethacin for the closure of patent ductus arteriosus. The
main concern for the pediatrician soliciting guidance was the
occurrence of oliguria as an adverse effect. In this case, we
retrieved a meta-analysis including eleven CRT in which both
agents were compared [7]. From the eleven CRT, oliguria was
Table 4. Calculation of expected frequencies combining efficacy and safety with data belonging to a CRT in which gemifloxacin
was assayed [6]. *=by rounding.
Responders to gemifloxacin Non-responders to gemifloxacin
Not withdrawn a=2546274/290=240* b=366274/290=34* Total not withdrawn=274
Withdrawn c=254616/290=14* d=36616/290=2* Total withdrawn=16
Total responders=254 Total non-responders=36 Total studied=290
doi:10.1371/journal.pone.0003580.t004
Table 5. Expected frequencies combining efficacy and safety
distributed according to the template shown in Table 3.
Responders not withdrawn Remaining patients Total
Gemifloxacin 240 50 290
Trovafloxacin 217 64 281
Data are from a CRT in which gemifloxacin and trovafloxacin were assayed [6].
doi:10.1371/journal.pone.0003580.t005
Table 6. Results of calculating NEAR and traditional efficacy
and safety variables with data obtained from a CRT in which
gemifloxacin was assayed versus trovafloxacin [6].
Lower limit 95%
confidence interval
Upper limit 95%
confidence interval
Efficacy OR 1.64 1.04 2.60
Safety OR 0.83 0.39 1.76
NEAR OR 1.40 0.93 2.12
Efficacy RR 1.08 1.01 1.16
Safety RR 0.99 0.95 1.03
NEAR RR 1.07 0.98 1.16
NNT 216 28 2198
NNH 2101 222 38
A lower limit of 95% confidence interval above 1.0 (except for NNT and NNH)
means that gemifloxacin is preferable to trovafloxacin. The minus sign in the
case of NNT indicates that fewer patients need to be treated with gemifloxacin
to obtain one further success; in the case of NNH, the minus sign means that
fewer patients need to be treated with gemifloxacin to produce one further
adverse event.
doi:10.1371/journal.pone.0003580.t006
Net Efficacy Adjusted for Risk
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may be seen that 191 infants received ibuprofen, ductal closure
occurring in 140 of them (73.3%). Another 179 were given
indomethacin and ductal closure occurred in 126 (70.4%).
Oliguria occurred in 6 infants treated with ibuprofen and in 27
treated with indomethacin. The authors concluded that ‘‘ibupro-
fen was as effective as indomethacin; likewise, in general, there
were no complications with the treatments, except for a risk
Figure 1. Graphic representation of traditional efficacy and safety odds ratio (OR) together with the OR for ‘‘net efficacy adjusted for
adverse reactions’’ (NEAR ). Data were extracted from trials comparing ibuprofen vs. indomethacin for the closure of patent ductus arteriosus [7];
tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [11]; warfarin vs. aspirin for preventing thromboembolic
events in patientssufferingatrialfibrillation[12]andmoreintensive vs.lessintensivestatintherapyincardiovasculardiseases[13]. When the lower limitof
the 95% confidence interval is above 1.0, the proband drug (first-mentioned in graphic footnotes) is better than the control one.
doi:10.1371/journal.pone.0003580.g001
Net Efficacy Adjusted for Risk
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reduction in suffering oliguria was not statistically analyzed by the
authors. In this manner, OR and RR for efficacy and NNT
revealed that both compounds had a similar efficacy; OR and RR
for safety, and NNH, indicated that ibuprofen is safer than
indomethacin. Expected frequencies calculation indicated that
ductal closure was obtained without suffering oliguria in 136 out of
191 patients (71.2%) in the ibuprofen arm and in 107 out of 179 in
the indomethacin arm (59.7%). Both NEAR OR and RR
confidence intervals confirmed that ibuprofen was significantly
better than indomethacin (Figure 1 and Table 7). Therefore, in
this case, our model helped to discriminate ibuprofen as a
statistically significant better option.
Examples with drugs recently introduced on the market
In the second setting, an appraisal of a new drug was performed.
Tigecycline is a novel antibiotic with in vitro activity against
microorganisms frequently associated to intra-abdominal infec-
tions; on the other hand, in hospitalized patients with complicated
infections, imipenem/cilastatin is the drug of choice. A multicenter
CRT studied the efficacy and safety of tigecycline as compared
with imipenem/cilastatin in complicated hospitalized intra-
abdominal infections [11]. Four hundred and eight clinically
evaluable patients received tigecyclin and 399 imipenem/cilasta-
tin. At the test-of-cure visit, 69.7% patients of the tigecyclin group
and 78.4% of the imipenem/cilastatin group were clinically cured.
When withdrawals from the study caused by drug problems were
computed, 6.5% in the tigecycline arm and 3.6% in the
imipenem/cilastatin arm were noted. The authors concluded that
‘‘tigecycline is an effective and well tolerated monotherapy option
for the treament of patients with complicated intra-abdominal
infections, with comparable efficacy to imipenem/cilastatin’’.
However, traditional OR and RR for efficacy and NNT indicate
that the control group was better than proband; no differences
were found for safety, except for NNH which was clearly
favourable to the control drug. Expected frequencies calculation
indicate that 266 out of 408 (65.2%) in the tigecyclin arm and 302
out of 399 (75.7%) in the imipenem/cilastatin one improved
without suffering adverse reactions. Results of our model (Figure 1
and Table 8) clearly indicated that imipenem/cilastatin, the
classical drug of choice, continued to be a better option than
tigecycline in treating this type of infection.
Cases in which disease prevention is the endpoint
A third setting is related to those studies in which preventing a
harmful event is the primary endpoint. Most of these studies
correspond to secondary prevention of events arising in the course
of chronic diseases, needing therefore long lasting treatments. In
these cases, there is no doubt that safety is a critical aspect. Given
the relevance of this setting, two examples will be shown.
A first example of this circumstance comes from a generalized
debate among cardiologists as to the use of warfarin versus aspirin
to prevent thromboembolic complications in chronic atrial
fibrillation. In this case a randomized 2-year comparative trial of
warfarin, aspirin and placebo was retrieved [12]. In calculating
NEAR, the data corresponding to placebo were not included. The
aspirin dose was 75 mg/day, and that of warfarin was adjusted by
the international normalized ratio. Of 335 patients treated with
warfarin, 330 did not suffer thromboembolic complications
(98.5%); of 336 patients treated with aspirin, 316 did not suffer
thromboembolic complications (94.0%). The authors concluded
that it was recommendable to use warfarin to prevent thrombo-
embolic complications, which today constitutes routine practice in
these patients. We found that traditional OR and RR for warfarin
efficacy as well as NNT significantly favored this compound; the
opposite was the case with the safety variables, all of them favoring
aspirin when severe gastrointestinal and pulmonary hemorrhage
were considered (23 versus eight in proband and control groups,
respectively). By calculating the expected frequencies, 307 out of
335 patients (91.6%) in the proband group and 308 out of 336 in
the control one (91.6%) were protected without suffering from
severe hemorrhage. When both NEAR OR and RR were
Table 7. Results of classical RR, NNT and NNH variables
together with NEAR RR for a CRT comparing ibuprofen vs.
indomethacin for the closure of patent ductus arteriosus [7].
Ibuprofen vs. indomethacin
95% Confidence intervals
Efficacy RR 1.04 0.92 1.18
Safety RR 1.14 1.07 1.22
NEAR RR 1.19 1.02 1.38
NNT 34 281 6
NNH 7 11 5
Graphic representation of NEAR OR may be seen in Figure 1.
doi:10.1371/journal.pone.0003580.t007
Table 8. Results of classical RR, NNT and NNH variables
together with the new NEAR RR for a CRT comparing
tigecycline versus imipenem/cilastatin in patients with
complicated intra-abdominal infections [11].
Tigecyclin vs. imipenem
95% Confidence intervals
Efficacy RR 0.89 0.82 0.96
Safety RR 0.97 0.94 1.00
NEAR RR 0.86 0.78 1.78
NNT 11 35 7
NNH 229 215 2229
Graphic representation of NEAR OR may be seen in Figure 1.
doi:10.1371/journal.pone.0003580.t008
Table 9. Results of classical RR, NNT and NNH variables
together with the new NEAR RR for two CRT comparing.
warfarin vs. aspirin for preventing thromboembolic events in
patients suffering atrial fibrillation [12] and more intensive vs.
less intensive statin therapy in cardiovascular diseases [13].
Warfarin vs. aspirin High vs. low dose statins
95% Confidence
intervals
95% Confidence
intervals
Efficacy RR 1.05 1.02 1.08 1.02 1.01 1.03
Safety RR 0.95 0.92 0.99 0.97 0.96 0.98
NEAR RR 1.00 0.96 1.05 0.99 0.98 1.00
NNT 222 214 262 271 249 2128
NNH 220 212 256 235 229 243
Graphic representation of OR may be seen in Figure 1.
doi:10.1371/journal.pone.0003580.t009
Net Efficacy Adjusted for Risk
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and Table 8). In view of these results, one wonders whether the
clinical benefit obtained is really so important as to continue
recommending warfarin for this kind of patients.
Another example of disease prevention comes from the more
intensive versus less intensive therapy with statins for secondary
reduction of cardiovascular events and stroke. A recently
published meta-analysis deals with this subject [13], in which
results of seven trials were pooled; pravastatin, simvastatin,
atorvastatin and lovastatin were the drugs studied; 13,641 of
14,768 patients (92.4%) receiving high dose therapy were
protected from myocardial events whereas 13,302 of 14,625
(91.0%) receiving low dose therapy were also protected. According
to the authors, a non-significant difference of 7.8% v.s. 5.3% of
patients (high versus low dose, respectively) discontinued drug
therapy as a consequence of an adverse event. The authors
concluded that ‘‘in summary, more intensive statin therapy is safe
and well-tolerated. It provides incremental benefits over and above
those of lower intensity statin therapy in the secondary prevention
of myocardial infarction and stroke in patients with known
coronary disease’’. Indeed, classical parameters confirm the
authors’ conclusion as to efficacy; however, as to safety, all the
variables indicate that low dose is preferable. Expected frequencies
calculation showed that with the high dose regime statins
protected 12,577 out of 14,768 patients (85.2%) without causing
ADR; this value was 12,597 out of 14,625 (86.1%) in the case of
the low dose regime. By adjusting efficacy to risk in one measure, it
is clearly seen that no significant differences exist between the two
treatment schedules (Figure 1 and Table 8). Therefore, since
muscle disturbances are a well known adverse effect of these drugs,
a more conservative recommendation as to using high dose may
be more suitable.
A comparison of expected vs. real frequencies
Finally, the accuracy of expected frequencies was tested against
frequency data corresponding to a CRT reported in the literature
[1]. This is one of the rare cases in which the authors detailed the
actual values of patients improved without suffering ADR; the
authors compared an unknown test drug with a standard one
jointly with hydrochlorothiazide to control blood pressure. With
these data we calculated the expected frequencies for each group,
comparing them with real frequencies. The results are summa-
rized in Table 10 (excluding drop-outs). As can be seen, expected
frequencies suitably fit actual values.
Discussion
NEAR OR and RR calculation represent a simple and useful
tool for combining risks and benefits in one easily understandable
measure. Moreover, data for calculation may be easily obtained
from published CRT. Lastly, NEAR may help in solving clinical
problems arising in practical settings. Therefore, the objectives
outlined in the Introduction have all been accomplished.
Nevertheless, certain topics deserve discussion.
First, although NEAR is a similar approach to a binary
composite endpoint defining ‘‘efficacy without ADR’’, it is not
exactly equivalent. Using a binary endpoint with such components
requires knowing the number of patients that improved without
being affected by ADR, which is the obstacle we have tried to
overcome with our method. Recently, a method for analyzing a
binary composite endpoint when there are missing data in
components has been reported [14], but such a mathematically
complex analysis is only viable when the CRT has been designed
with the binary endpoint ‘‘efficacy without ADR’’ as the main
variable. Our approach lends support to this kind of analysis and
emphasizes the necessity of designing clinical trials with these
composite endpoints in which efficacy is balanced against safety.
Second, there is no doubt that mathematical formulations
developed by other authors are highly interesting. For instance,
the use of risk:benefit contours in cancer therapy [2] may represent
a relevant contribution. Similarly, the conversion of traditional
NNT into NNTus (NNT unqualified success) and NNTuf (NNT
unmitigated failure) [3], which allow us to combine efficacy and
safety, is also an attractive approach. Perhaps other proposals,
although evidently relevant from a theoretical point of view [1,4],
may be excessively complex for translation to clinical practice.
Anyhow, it is clear that none of these formulations have attained
the popularity of NNT and NNH [15]; the likely reason for this is
that these parameters represent an easily understandable and
simple concept, i.e. number of patients needed to treat to obtain
one further success or one additional adverse event, respectively.
Theoretically, an NNT/NNH ratio could be a useful measure
combining efficacy and safety, but calculating these parameters
may produce numbers with negative or positive values, which
makes it difficult to interpret a ratio obtained by dividing them. In
addition, when their confidence intervals include negative and
positive values the possibility of obtaining rational results is
practically null. For this reason, we opted for a procedure in which
arithmetical signs were avoided.
Third, an important item in our model is the interpretation of
results. In this respect, these new measures must be interpreted
rigorously within the context of the problem features, caution
being exercised in extrapolating conclusions beyond this frontier.
In other words, usefulness of this new model depends on suitably
selecting those efficacy (benefit) and safety (risk) variables that best
define the problem. The varying importance of these variables
depends on the case under consideration. For instance, the risk of
pruritus produced by an anticancer treatment is less important
than the benefit; whereas it becomes more important in cases only
needing antiacid therapy. In this respect, efficacy variables are
thoroughly reported in most published reports of CRT, and
selecting one of them is extremely easy, whereas adverse reaction
Table 10. Comparison of real and expected frequencies with data extracted from a clinical trial in which hydrochlorothiazide plus
a test drug (T) was compared with hydrochlorothiazide plus a standard drug (S) in hypertensive patients [1].
Responders without ADR Responders suffering ADR Non-responders non suffering ADR Non-responders suffering ADR
Actual
value
Expected
frequency
Actual
value
Expected
frequency
Actual
value
Expected
frequency
Actual
value
Expected
frequency
HCTZ+T 5 05 4 1 5 3 1 4 9 1 41 0 2 42 8
HCTZ+S 1 0 1 1 0 8 4 03 3 8 27 5 1 62 3
doi:10.1371/journal.pone.0003580.t010
Net Efficacy Adjusted for Risk
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selecting a safety variable, the concrete clinical problem intended
to treat should be considered (v.g. oliguria and NSAID). In the
case of more general analyses, an appropriate variable for safety
may be the proportion of patients that discontinued drug
treatment as a consequence of an ADR (the case of high v.s. low
dose statins).
Continuing with result interpretation, the 95% CIs used in our
procedure are widely used in OR and RR calculation, and,
consequently, the assumptions under which these CIs are correct
are the same for NEAR OR and NEAR RR. In this respect,
although the CIs were calculated with ‘‘transformed’’ (expected)
values, theoretically these ‘‘transformed 95% CIs’’ must presum-
ably have a similar level of certainty to that obtained by using real
(observed) values. In fact, on calculating CIs with the data shown
in Table 10, in which observed and expected values obtained in a
real clinical trial [1] are shown, the 95% CIs for OR and RR for
observed values were practically identical to those calculated with
expected values. Indeed, in the case of observed values, the NEAR
OR was 0.357 (0.238–0.535) and in the case of expected values the
result was 0.350 (0.235–0.520). For RR the results were similar.
Therefore assumptions applied to ‘‘observed 95% CIs’’ may be
similarly applied to ‘‘transformed 95% CIs’’. However, in practice,
when the upper or the lower limit of NEAR OR or NEAR RR
95% CIs are quite close to 1.0, say 0.95 or 1.05, a wise use of the
measure should require ‘‘a post hoc’’ discussion and perhaps a
revision of complementary information; a similar situation may
arise when considering wide CIs and/or small sample sizes.
Anyhow, these are not specific problems of NEAR interpretation;
these are general problems of working with CIs.
Fourth, according to evidence-based medicine, the quality of
clinical trials analyzed is a critical factor for obtaining reliable
conclusions. In fact, only high quality CRT or high-quality CRT-
based meta-analyses should be employed. In this respect, a simple
five-score scale to measure CRT quality has gained wide
acceptance [16]. Although Tables 7, 8 and 9 do not show these
scores (to avoid cluttering), it can be said that the data used were of
high quality.
Fifth, together with quality, the CRT employed must satisfy
other technical requirements. So, only those trials describing
efficacy and safety as categorical variables may be analyzed by our
procedure. In contrast, those studies in which efficacy and safety
are not measured in the same series of patients cannot be used.
Special care must be taken with ADR data, since a single patient
may often present several adverse symptoms, so the number of
ADR may be higher than the number of patients, which can
produce errors in calculation. Finally, a limitation of working with
categorical variables is that the degree of improvement or
deterioration balance may only be determined when the authors
report such detail. Indeed, when the authors indicate that the
endpoint is, say, an increase in the magnitude of parameter x, we
can determine the degree of improvement; but if they only indicate
that the endpoint is, say, any decrease of temperature, the
magnitude of the antipyretic effect cannot be determined.
Sixth, when the results obtained with traditional tools for
measuring efficacy or safety separately were compared with
NEAR OR or NEAR RR, it is clear that these new tools tend to
yield balanced results. In this manner, we can have a global and
mathematical appraisal of two therapeutic options by means of a
single view.
Finally, we leave open the possibility of using NEAR OR or
NEAR RR. In this respect, there is a debate as to which
parameter, OR or RR, should be used [17]. Apparently, some
authors think that preferring one to another is a matter of patient
setting as well as the type of design used in the study, i.e.
experimental versus observational. Therefore, we have presented
the two parameters to leave open the possibility of using one over
the other.
In conclusion, NEAR representing overall risk:benefit as
measured in the present study may contribute to improving
knowledge of drug usefulness and facilitate the rational choice of
drugs by prescribers. Within these general comments it must be
emphasized that narrative results without accurate data about
particular patients affected by ADR are often the only source of
information, which radically contrasts with the almost exquisite
and detailed manner in which efficacy is reported. In this respect,
our measure represents an effort to change this way of thinking.
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